Spanish in vitro diagnostics (IVD) firm Werfen and its Bedford, MA-based subsidiary Instrument Laboratory (IL) have acquired Accriva, a point-of-care (POC) diagnostics company specialized in systems for coagulation testing and antiplatelet therapy response. The transaction, which closed yesterday, but for which details have not been disclosed, will see Accriva become part of IL and continue to operate out of its facilities in San Diego, CA, where some 460 staff are employed.

IL is a global developer, manufacturer, and distributor of IVD instruments, reagents, and data management solutions for the hospital and clinical laboratory markets. The firm says the acquisition of Accriva will boost its position in POC critical care testing, allow it to establish a presence in hospital-based POC hemostasis testing, and bolster its existing capabilities in laboratory hemostasis testing. “The acquisition of Accriva strengthens our leadership in hemostasis, critical care, and patient blood management testing,” said Ramon Benet, CEO at IL. “We see great synergy between our organizations and look forward to further impacting positive clinical outcomes and reducing healthcare costs in point-of-care testing with the breadth of this comprehensive portfolio.”

“We are proud of the value we have created,” added Scott Cramer, president and CEO of Accriva Diagnostics.  “With our third consecutive year of record sales, significant operational efficiencies, and new product pipeline, we foresee significant growth ahead. Now, the tremendous resources, expertise, and global reach of Werfen and IL will accelerate this trajectory even further.”

Just last month, IL reported FDA clearance for its new GEM® Premier 5000 Critical Care Testing System for hospital POC testing. IL’s parent organization Werfen is a global IVD firm based in Barcelona. Werfen’s subsidiaries include Inova Diagnostics, an autoimmunity specialist, Biokit, which offers diagnostic reagents and clinical systems for infectious diseases, and Systelab, which specializes in laboratory and hospital software solutions. 

Previous articleDiscovery of Bacteria’s Immune System-Avoiding Strategy May Lead to New Therapies
Next articleTrump Keeps Collins at NIH Helm, for the Moment